Citigroup
CLVS

Citigroup’s Clovis Oncology, Inc. CLVS Stock Holding History

Citigroup’s Portfolio CLVS Stock Details CLVS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q2 		– Sell
-50,000
Closed -$101K – 6855
2022
Q1 		$101K Buy
+50,000
New +$98.2K ﹤0.01% 4412
2021
Q1 		– Sell
-126,500
Closed -$607K – 7711
2020
Q4 		$607K Buy
126,500
+23,000
+22% +$116K ﹤0.01% 4030
2020
Q3 		$603K Buy
103,500
+40,600
+65% +$243K ﹤0.01% 3700
2020
Q2 		$425K Sell
62,900
-8,000
-11% -$60.6K ﹤0.01% 4414
2020
Q1 		$451K Sell
70,900
-45,600
-39% -$366K ﹤0.01% 3961
2019
Q4 		$1.22M Buy
116,500
+26,600
+30% +$193K ﹤0.01% 3559
2019
Q3 		$354K Buy
89,900
+57,900
+181% +$468K ﹤0.01% 4662
2019
Q2 		$476K Buy
32,000
+2,600
+9% +$47K ﹤0.01% 4476
2019
Q1 		$730K Buy
29,400
+4,500
+18% +$113K ﹤0.01% 3748
2018
Q4 		$447K Sell
24,900
-4,100
-14% -$83.8K ﹤0.01% 4250
2018
Q3 		$852K Buy
29,000
+18,000
+164% +$697K ﹤0.01% 3673
2018
Q2 		$500K Sell
11,000
-4,000
-27% -$195K ﹤0.01% 4104
2018
Q1 		$792K Sell
15,000
-6,500
-30% -$379K ﹤0.01% 3485
2017
Q4 		$1.46M Buy
21,500
+1,400
+7% +$97.9K ﹤0.01% 2957
2017
Q3 		$1.66M Sell
20,100
-14,500
-42% -$1.15M ﹤0.01% 2866
2017
Q2 		$3.24M Sell
34,600
-5,500
-14% -$337K ﹤0.01% 2092
2017
Q1 		$2.55M Buy
40,100
+18,400
+85% +$1.12M ﹤0.01% 2239
2016
Q4 		$964K Buy
21,700
+2,000
+10% +$70.4K ﹤0.01% 3733
2016
Q3 		$710K Buy
19,700
+11,200
+132% +$240K ﹤0.01% 3579
2016
Q2 		$117K Sell
8,500
-43,800
-84% -$640K ﹤0.01% 4956
2016
Q1 		$1M Sell
52,300
-32,500
-38% -$688K ﹤0.01% 3339
2015
Q4 		$2.97M Buy
84,800
+32,100
+61% +$2.07M ﹤0.01% 2169
2015
Q3 		$4.85M Buy
52,700
+32,500
+161% +$2.81M ﹤0.01% 1691
2015
Q2 		$1.77M Buy
+20,200
New +$1.73M ﹤0.01% 2639

Other funds holding CLVS

IA
IFP Advisors Tampa, Florida $4.82B AUM 20.19% 1-Year Est. Return
Macquarie Group
Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return
CAS
Coppell Advisory Solutions Coppell, Texas $170M AUM 13.42% 1-Year Est. Return
CASC
Coppell Advisory Solutions Corp Coppell, Texas $531M AUM
STB
S&T Bank Indiana, Pennsylvania $268M AUM 39.92% 1-Year Est. Return
MCM
MAI Capital Management Independence, Ohio $17.7B AUM 18.87% 1-Year Est. Return
WS
Wedbush Securities Los Angeles, California $3.43B AUM 24.13% 1-Year Est. Return
FFWM
Future Financial Wealth Management Cincinnati, Ohio $155M AUM 13% 1-Year Est. Return
NFSG
Newbridge Financial Services Group Boca Raton, Florida $608M AUM 31.28% 1-Year Est. Return
Qube Research & Technologies (QRT)
Qube Research & Technologies (QRT) London, United Kingdom $89.9B AUM 20.22% 1-Year Est. Return

Citigroup's CLVS Position: Q4 2022 in Review

Citigroup sold out of Clovis Oncology, Inc. (CLVS) in Q4 2022, closing a stake of 1,752 shares — an estimated $2K sold.

Citigroup first reported a position in CLVS in Q2 2013 and held it in 38 quarters. The position peaked at $27.2M in Q1 2017. 15 funds tracked by Wall St. Rank hold CLVS as of Q4 2022.

  • Citigroup reported no remaining Clovis Oncology, Inc. position as of Q4 2022 after selling out during the quarter.
  • Citigroup sold 1,752 Clovis Oncology, Inc. shares in Q4 2022, an estimated $2K.
  • Citigroup first reported a position in Clovis Oncology, Inc. in Q2 2013 and held it in 38 quarters.
  • Citigroup's Clovis Oncology, Inc. position peaked at $27.2M in Q1 2017.
  • 15 funds tracked by Wall St. Rank held Clovis Oncology, Inc. as of Q4 2022.

Based on Citigroup's 13F filing for Q4 2022, filed 9 Feb 2023.